1
|
Breukers J, Ven K, Struyfs C, Ampofo L, Rutten I, Imbrechts M, Pollet F, Van Lent J, Kerstens W, Noppen S, Schols D, De Munter P, Thibaut HJ, Vanhoorelbeke K, Spasic D, Declerck P, Cammue BPA, Geukens N, Thevissen K, Lammertyn J. FLUIDOT: A Modular Microfluidic Platform for Single-Cell Study and Retrieval, with Applications in Drug Tolerance Screening and Antibody Mining. SMALL METHODS 2023; 7:e2201477. [PMID: 36642827 DOI: 10.1002/smtd.202201477] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/11/2022] [Revised: 12/21/2022] [Indexed: 06/17/2023]
Abstract
Advancements in lab-on-a-chip technologies have revolutionized the single-cell analysis field. However, an accessible platform for in-depth screening and specific retrieval of single cells, which moreover enables studying diverse cell types and performing various downstream analyses, is still lacking. As a solution, FLUIDOT is introduced, a versatile microfluidic platform incorporating customizable microwells, optical tweezers and an interchangeable cell-retrieval system. Thanks to its smart microfluidic design, FLUIDOT is straightforward to fabricate and operate, rendering the technology widely accessible. The performance of FLUIDOT is validated and its versatility is subsequently demonstrated in two applications. First, drug tolerance in yeast cells is studied, resulting in the discovery of two treatment-tolerant populations. Second, B cells from convalescent COVID-19 patients are screened, leading to the discovery of highly affine, in vitro neutralizing monoclonal antibodies against SARS-CoV-2. Owing to its performance, flexibility, and accessibility, it is foreseen that FLUIDOT will enable phenotypic and genotypic analysis of diverse cell samples and thus elucidate unexplored biological questions.
Collapse
Affiliation(s)
- Jolien Breukers
- Department of Biosystems, Biosensors group, KU Leuven, Willem de Croylaan 42, Leuven, 3001, Belgium
- LISCO, KU Leuven Institute for Single Cell Omics, ON4 Herestraat 49, Leuven, 3000, Belgium
| | - Karen Ven
- Department of Biosystems, Biosensors group, KU Leuven, Willem de Croylaan 42, Leuven, 3001, Belgium
- LISCO, KU Leuven Institute for Single Cell Omics, ON4 Herestraat 49, Leuven, 3000, Belgium
- MabMine: KU Leuven Single B Cell Mining Platform, KU Leuven, ON2 Herestraat 49, 3000, Leuven, Belgium
| | - Caroline Struyfs
- Centre of Microbial and Plant Genetics, KU Leuven, Kasteelpark Arenberg 20, Leuven, 3001, Belgium
| | - Louanne Ampofo
- Department of Biosystems, Biosensors group, KU Leuven, Willem de Croylaan 42, Leuven, 3001, Belgium
- MabMine: KU Leuven Single B Cell Mining Platform, KU Leuven, ON2 Herestraat 49, 3000, Leuven, Belgium
- PharmAbs, The KU Leuven Antibody Center, KU Leuven, ON 2 Herestraat 49, Leuven, 3000, Belgium
- Laboratory for Therapeutic and Diagnostic Antibodies, KU Leuven, ON2 Herestraat 49, Leuven, 3000, Belgium
| | - Iene Rutten
- Department of Biosystems, Biosensors group, KU Leuven, Willem de Croylaan 42, Leuven, 3001, Belgium
- LISCO, KU Leuven Institute for Single Cell Omics, ON4 Herestraat 49, Leuven, 3000, Belgium
| | - Maya Imbrechts
- MabMine: KU Leuven Single B Cell Mining Platform, KU Leuven, ON2 Herestraat 49, 3000, Leuven, Belgium
- PharmAbs, The KU Leuven Antibody Center, KU Leuven, ON 2 Herestraat 49, Leuven, 3000, Belgium
- Laboratory for Therapeutic and Diagnostic Antibodies, KU Leuven, ON2 Herestraat 49, Leuven, 3000, Belgium
| | - Francesca Pollet
- Department of Biosystems, Biosensors group, KU Leuven, Willem de Croylaan 42, Leuven, 3001, Belgium
| | - Julie Van Lent
- Department of Biosystems, Biosensors group, KU Leuven, Willem de Croylaan 42, Leuven, 3001, Belgium
| | - Winnie Kerstens
- Translational Platform Virology and Chemotherapy, Rega Institute, KU Leuven, Rega - Herestraat 49, Leuven, 3000, Belgium
| | - Sam Noppen
- Laboratory of Virology and Chemotherapy, Rega Institute, KU Leuven, Rega - Herestraat 49, Leuven, 3000, Belgium
| | - Dominique Schols
- Laboratory of Virology and Chemotherapy, Rega Institute, KU Leuven, Rega - Herestraat 49, Leuven, 3000, Belgium
| | - Paul De Munter
- Department of Internal Medicine, University Hospitals Leuven, UZ Herestraat 49, Leuven, 3000, Belgium
- Laboratory for Clinical Infectious and Inflammatory Disorders, KU Leuven, UZ Herestraat 49, Leuven, 3000, Belgium
| | - Hendrik Jan Thibaut
- Translational Platform Virology and Chemotherapy, Rega Institute, KU Leuven, Rega - Herestraat 49, Leuven, 3000, Belgium
| | - Karen Vanhoorelbeke
- MabMine: KU Leuven Single B Cell Mining Platform, KU Leuven, ON2 Herestraat 49, 3000, Leuven, Belgium
- PharmAbs, The KU Leuven Antibody Center, KU Leuven, ON 2 Herestraat 49, Leuven, 3000, Belgium
- Laboratory for Thrombosis Research, KU Leuven Campus Kulak Kortrijk, Etienne Sabbelaan 53, Kortrijk, 8500, Belgium
| | - Dragana Spasic
- Department of Biosystems, Biosensors group, KU Leuven, Willem de Croylaan 42, Leuven, 3001, Belgium
| | - Paul Declerck
- MabMine: KU Leuven Single B Cell Mining Platform, KU Leuven, ON2 Herestraat 49, 3000, Leuven, Belgium
- PharmAbs, The KU Leuven Antibody Center, KU Leuven, ON 2 Herestraat 49, Leuven, 3000, Belgium
- Laboratory for Therapeutic and Diagnostic Antibodies, KU Leuven, ON2 Herestraat 49, Leuven, 3000, Belgium
| | - Bruno P A Cammue
- Centre of Microbial and Plant Genetics, KU Leuven, Kasteelpark Arenberg 20, Leuven, 3001, Belgium
| | - Nick Geukens
- MabMine: KU Leuven Single B Cell Mining Platform, KU Leuven, ON2 Herestraat 49, 3000, Leuven, Belgium
- PharmAbs, The KU Leuven Antibody Center, KU Leuven, ON 2 Herestraat 49, Leuven, 3000, Belgium
- Laboratory for Therapeutic and Diagnostic Antibodies, KU Leuven, ON2 Herestraat 49, Leuven, 3000, Belgium
| | - Karin Thevissen
- Centre of Microbial and Plant Genetics, KU Leuven, Kasteelpark Arenberg 20, Leuven, 3001, Belgium
| | - Jeroen Lammertyn
- Department of Biosystems, Biosensors group, KU Leuven, Willem de Croylaan 42, Leuven, 3001, Belgium
- LISCO, KU Leuven Institute for Single Cell Omics, ON4 Herestraat 49, Leuven, 3000, Belgium
- MabMine: KU Leuven Single B Cell Mining Platform, KU Leuven, ON2 Herestraat 49, 3000, Leuven, Belgium
- LIMNI, KU Leuven Institute for Micro- and Nanoscale Integration, Celestijnenlaan 200F, Leuven, 3001, Belgium
| |
Collapse
|
4
|
Li Y, Li P, Ke Y, Yu X, Yu W, Wen K, Shen J, Wang Z. A rare monoclonal antibody discovery based on indirect competitive screening of a single hapten-specific rabbit antibody secreting cell. Analyst 2022; 147:2942-2952. [PMID: 35674177 DOI: 10.1039/d2an00678b] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
A rare antibody that is able to tolerate physio-chemical factors is preferred and highly demanded in diagnosis and therapy. Rabbit monoclonal antibodies (RmAbs) are distinguished owing to their high affinity and stability. However, the efficiency and availability of traditional methods for RmAb discovery are limited, particularly for small molecules. Here, we present an indirect competitive screening method in nanowells, named CSMN, for single rabbit antibody-secreting cells (ASCs) selection with 20.6 h and propose an efficient platform for RmAb production against small molecules within 5.8 days for the first time. Chloramphenicol (CAP) as an antibacterial agent poses a great threat to public health. We applied CSMN to select CAP-specific ASCs and produced one high-affinity RmAb, surprisingly showed extremely halophilic properties with an IC50 of 0.08 ng mL-1 in the saturated salt solution, which has not yet been seen for other antibodies. The molecular dynamic simulation showed that the negatively charged surface improved the stability of the RmAb structure with additional disulfide bonds compared with mouse antibodies. Moreover, the reduced solvent accessible surface area of the binding pocket increased the interactions of RmAb with CAP in a saturated salt solution. Furthermore, RmAb was used to develop an immunoassay for the detection of CAP in real biological samples with simple pretreatment, shorter assay time, and higher sensitivity. The results demonstrated that the practical and efficient CSMN is suitable for rare RmAb discovery against small molecules.
Collapse
Affiliation(s)
- Yuan Li
- College of Veterinary Medicine, China Agricultural University, Beijing Key Laboratory of Detection Technology for Animal-Derived Food Safety, Beijing Laboratory for Food Quality and Safety, 100193 Beijing, People's Republic of China.
| | - Peipei Li
- College of Veterinary Medicine, China Agricultural University, Beijing Key Laboratory of Detection Technology for Animal-Derived Food Safety, Beijing Laboratory for Food Quality and Safety, 100193 Beijing, People's Republic of China.
| | - Yuebin Ke
- Key Laboratory of Molecular Epidemiology of Shenzhen, Shenzhen Center for Disease Control and Prevention, 518000 Shenzhen, China
| | - Xuezhi Yu
- College of Veterinary Medicine, China Agricultural University, Beijing Key Laboratory of Detection Technology for Animal-Derived Food Safety, Beijing Laboratory for Food Quality and Safety, 100193 Beijing, People's Republic of China.
| | - Wenbo Yu
- College of Veterinary Medicine, China Agricultural University, Beijing Key Laboratory of Detection Technology for Animal-Derived Food Safety, Beijing Laboratory for Food Quality and Safety, 100193 Beijing, People's Republic of China.
| | - Kai Wen
- College of Veterinary Medicine, China Agricultural University, Beijing Key Laboratory of Detection Technology for Animal-Derived Food Safety, Beijing Laboratory for Food Quality and Safety, 100193 Beijing, People's Republic of China.
| | - Jianzhong Shen
- College of Veterinary Medicine, China Agricultural University, Beijing Key Laboratory of Detection Technology for Animal-Derived Food Safety, Beijing Laboratory for Food Quality and Safety, 100193 Beijing, People's Republic of China.
| | - Zhanhui Wang
- College of Veterinary Medicine, China Agricultural University, Beijing Key Laboratory of Detection Technology for Animal-Derived Food Safety, Beijing Laboratory for Food Quality and Safety, 100193 Beijing, People's Republic of China.
| |
Collapse
|
5
|
Strohl WR, Ku Z, An Z, Carroll SF, Keyt BA, Strohl LM. Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants. BioDrugs 2022; 36:231-323. [PMID: 35476216 PMCID: PMC9043892 DOI: 10.1007/s40259-022-00529-7] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/21/2022] [Indexed: 12/15/2022]
Abstract
The COVID-19 pandemic is now approaching 2 years old, with more than 440 million people infected and nearly six million dead worldwide, making it the most significant pandemic since the 1918 influenza pandemic. The severity and significance of SARS-CoV-2 was recognized immediately upon discovery, leading to innumerable companies and institutes designing and generating vaccines and therapeutic antibodies literally as soon as recombinant SARS-CoV-2 spike protein sequence was available. Within months of the pandemic start, several antibodies had been generated, tested, and moved into clinical trials, including Eli Lilly's bamlanivimab and etesevimab, Regeneron's mixture of imdevimab and casirivimab, Vir's sotrovimab, Celltrion's regdanvimab, and Lilly's bebtelovimab. These antibodies all have now received at least Emergency Use Authorizations (EUAs) and some have received full approval in select countries. To date, more than three dozen antibodies or antibody combinations have been forwarded into clinical trials. These antibodies to SARS-CoV-2 all target the receptor-binding domain (RBD), with some blocking the ability of the RBD to bind human ACE2, while others bind core regions of the RBD to modulate spike stability or ability to fuse to host cell membranes. While these antibodies were being discovered and developed, new variants of SARS-CoV-2 have cropped up in real time, altering the antibody landscape on a moving basis. Over the past year, the search has widened to find antibodies capable of neutralizing the wide array of variants that have arisen, including Alpha, Beta, Gamma, Delta, and Omicron. The recent rise and dominance of the Omicron family of variants, including the rather disparate BA.1 and BA.2 variants, demonstrate the need to continue to find new approaches to neutralize the rapidly evolving SARS-CoV-2 virus. This review highlights both convalescent plasma- and polyclonal antibody-based approaches as well as the top approximately 50 antibodies to SARS-CoV-2, their epitopes, their ability to bind to SARS-CoV-2 variants, and how they are delivered. New approaches to antibody constructs, including single domain antibodies, bispecific antibodies, IgA- and IgM-based antibodies, and modified ACE2-Fc fusion proteins, are also described. Finally, antibodies being developed for palliative care of COVID-19 disease, including the ramifications of cytokine release syndrome (CRS) and acute respiratory distress syndrome (ARDS), are described.
Collapse
Affiliation(s)
| | - Zhiqiang Ku
- Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Sciences Center, Houston, TX USA
| | - Zhiqiang An
- Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Sciences Center, Houston, TX USA
| | | | | | | |
Collapse
|
6
|
Sun H, Hu N, Wang J. Application of Microfluidic Technology in Antibody Screening. Biotechnol J 2022; 17:e2100623. [PMID: 35481726 DOI: 10.1002/biot.202100623] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2021] [Revised: 04/13/2022] [Accepted: 04/23/2022] [Indexed: 11/07/2022]
Abstract
Specific antibodies are widely used in the biomedical field. Current screening methods for specific antibodies mainly involve hybridoma technology and antibody engineering techniques. However, these technologies suffer from tedious screening processes, long preparation periods, high costs, low efficiency, and a degree of automation, which have become a bottleneck for the screening of specific antibodies. To overcome these difficulties, microfluidics has been developed as a promising technology for high-throughput screening and high purity of antibody. In this review, we provide an overview of the recent advances in microfluidic applications for specific antibody screening. In particular, hybridoma technology and four antibody engineering techniques (including phage display, single B cell antibody screening, antibody expression, and cell-free protein synthesis) based on microfluidics have been introduced, challenges, and the future outlook of these technologies are also discussed. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Heng Sun
- Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing, 400044, China
| | - Ning Hu
- Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing, 400044, China
| | - Jianhua Wang
- Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing, 400044, China
| |
Collapse
|